Transcatheter Tricuspid Valve Interventions: A Triumph for Transcatheter Procedures?

Abstract

Tricuspid regurgitation (TR) is a common valvular pathology, estimated to affect 1.6 million people in the United States alone. Even though guidelines recommend either medical therapy or surgical treatment for TR, the misconception of TR as a benign disease along with the high mortality rates of surgical intervention led to undertreating this disease and commonly describing it as a “forgotten” valve. Recently, the development of transcatheter interventions for TR show promising potential for use in the clinical setting. There are currently few approved and numerous tested percutaneously delivered devices, which can be categorized, based on their mechanism of action, to either valve repair or valve replacement procedures. Both procedures were tested in clinical trials and show an echocardiographic reduction in TR sustained for at least 1 year after the procedure, as well as symptom relief and functional improvement of the patients. Device selection should be personalized, taking into consideration the anatomy of each valve and the available options at each heart center. Moreover, appropriate patient selection and timing of the procedure are also crucial for the success of the procedure. In this review, we analyze the clinical trials available for all devices currently approved or tested, aiming to provide a comprehensive summary of the most recent evidence in the field of transcatheter TR interventions.

The Application of Precision Medicine in Structural Heart Diseases: A Step towards the Future

“…Against this background, different approaches and devices have been utilized. Transcatheter edge-to-edge repair, transcatheter tricuspid valve replacement, annuloplasty, and heterotopic caval valve implantation have been performed by interventional cardiologists [74]. Although edge-toedge repair seems to be a step in front of the other methods, its results remain suboptimal.…”